Abstract

The invention provides compounds of formula: The invention provides compounds of formula: The invention provides compounds of formula: Wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention provides compositions and systems that allow the sensitive determination of the level of creatinine in a particular solution. Through the optimisation of enzymatic methods to detect creatinine the real-time determination of creatinine levels and creatinine clearance rates are also provided, allowing the real-time monitoring of kidney function. This is considered to be useful both in the monitoring of live subjects, and in the monitoring of isolated organs, such as a kidney, intended for transplantation.

IPC Classes  ?

• G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine
• C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention relates to immunogenic compositions, and in particular, to immunogenic compositions for preventing, treating or ameliorating human rhinovirus (RV) infections. The invention is especially concerned with RV VP0 peptides (or proteins) and polynucleotides encoding such peptides, and their use in immunogenic compositions for eliciting an immune response and preventing rhinovirus infections.

IPC Classes  ?

• A61K 39/125 - Picornaviridae, e.g. calicivirus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

An implant system for implantation at a joint. The implant system includes an implant device with a body portion having first and second ends, and a first elongate member, extending from the first or second end of the body portion. The implant system has a corresponding fixation device with at least one latching element. The first elongate member has at least one cooperating element capable of cooperating with the at least one latching element of the fixation device in use.

IPC Classes  ?

• A61F 2/30 - Joints
• A61B 17/56 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor
• A61F 2/38 - Joints for elbows or knees
• A61F 2/46 - Special tools for implanting artificial joints

Abstract

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards5 to potency properties at the GIP receptor. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

IPC Classes  ?

• C07K 14/605 - Glucagons
• C07K 14/575 - Hormones
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The invention relates to inhibitors of Von Willebrand Factor (VWF), and particularly to anti-VWF antibodies. The invention extends to compositions comprising the inhibitors, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the inhibitors, for example in therapy and diagnosis of conditions caused by platelet-mediated aggregation, including various cardiovascular diseases, such as acquired thrombotic thrombocytopenia purpura (aTTP), ischemic stroke and atherosclerosis.

IPC Classes  ?

• C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

22 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and/or reducing calorie intake, and related purposes.

IPC Classes  ?

• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• C07K 14/575 - Hormones
• C07K 14/585 - Calcitonins
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Analogues of PYY differing from native human PYY by substitution of Ser23 with Ala23, Glu23, Lys23, Gln23 or AIB23. Further optional features include substitutions at further positions, loss of the Tyr1 residue of native human PYY and amidation of the C-terminus. Suitable for use as pharmaceuticals for treating and preventing disorders, in particular diabetes and obesity.

IPC Classes  ?

• C07K 14/575 - Hormones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The invention relates to Von Willebrand Factor (VWF) antibodies, and particularly, although not exclusively, to antibodies which target the C1-C6 domain of VWF. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of using the antibodies, for example in therapy and diagnosis of conditions caused by platelet-mediated aggregation, including various cardiovascular diseases, such as acquired thrombotic thrombocytopenic purpura (aTTP), ischemic stroke and atherosclerosis.

IPC Classes  ?

• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors

Abstract

An implant system for implantation at a joint. The implant system includes an implant device with a body portion having first and second ends, and a first elongate member, extending from the first or second end of the body portion. The implant system has a corresponding fixation device with at least one latching element. The first elongate member has at least one cooperating element capable of cooperating with the at least one latching element of the fixation device in use.

IPC Classes  ?

• A61F 2/30 - Joints
• A61F 2/38 - Joints for elbows or knees
• A61B 17/56 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor
• A61F 2/46 - Special tools for implanting artificial joints

Abstract

The present invention relates to retroviral vectors, particularly lentiviral vectors, comprising a modified retroviral RNA sequence that is codon-substituted and comprises a reduced number of retroviral open-reading frames, and wherein the retroviral vector is pseudotyped with hemagglutinin-neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, methods of making the same and uses thereof.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• C12N 7/02 - Recovery or purification
• C12N 9/22 - Ribonucleases
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12N 9/76 - TrypsinChymotrypsin
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to retroviral vectors, particularly lentiviral vectors, comprising a modified retroviral RNA sequence that is codon-substituted and comprises a reduced number of retroviral open-reading frames, and wherein the retroviral vector is pseudotyped with hemagglutinin- neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, methods of making the same and uses thereof.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 15/867 - Retroviral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present invention relates to combination treatments for cystic fibrosis, particularly combinations of modulators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and gene therapy.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/404 - Indoles, e.g. pindolol
• A61P 11/00 - Drugs for disorders of the respiratory system
• C12N 15/86 - Viral vectors

Abstract

La présente invention concerne des composés de formule (I). Les substituants sont définis en détail dans la fiche technique. Les composés sont des inhibiteurs puissants de GCN2 et ont d’excellentes caractéristiques pharmacocinétiques. Les composés sont utiles pour le traitement ou la prévention d’une variété de conditions, en particulier le cancer. L’invention concerne également des compositions pharmaceutiques comprenant les composés de l’invention et des utilisations des composés et des compositions.

IPC Classes  ?

• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61P 11/06 - Antiasthmatics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems

Abstract

The invention provides compounds of formula (I) Wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61P 11/06 - Antiasthmatics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine

Abstract

The present invention relates to combination treatments for cystic fibrosis, particularly combinations of modulators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and gene therapy.

IPC Classes  ?

• A61P 11/12 - Mucolytics
• C07D 215/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to combination treatments for cystic fibrosis, particularly combinations of modulators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and gene therapy.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/12 - Mucolytics
• C07D 215/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

IPC Classes  ?

• A61P 9/12 - Antihypertensives
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention relates to immunogenic compositions, and in particular, to immunogenic compositions for preventing, treating or ameliorating human rhinovirus (RV) infections. The invention is especially concerned with RV VPo peptides (or proteins) and polynucleotides encoding such peptides, and their use in immunogenic compositions for eliciting an immune response and preventing rhinovirus infections.

IPC Classes  ?

• A61K 39/125 - Picornaviridae, e.g. calicivirus
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 14/095 - Rhinovirus

Abstract

The invention provides compounds of formula I, wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions. The invention provides compounds of formula I, wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 513/04 - Ortho-condensed systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention relates to immunogenic compositions, and in particular, to immunogenic compositions for preventing, treating or ameliorating human rhinovirus (RV) infections. The invention is especially concerned with RV VPo peptides (or proteins) and polynucleotides encoding such peptides, and their use in immunogenic compositions for eliciting an immune response and preventing rhinovirus infections.

IPC Classes  ?

• A61K 39/125 - Picornaviridae, e.g. calicivirus
• C07K 14/095 - Rhinovirus
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The invention provides compounds of formula I, wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 513/04 - Ortho-condensed systems

Abstract

The invention provides compounds of formula: Wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone

Abstract

Analogues of PYY differing from native human PYY by substitution of Ser23 with Ala23, Glu23, Lys23, Gln23 or AIB23. Further optional features include substitutions at further positions, loss of the Tyr1 residue of native human PYY and amidation of the C-terminus. Suitable for use as pharmaceuticals for treating and preventing disorders, in particular diabetes and obesity.

IPC Classes  ?

• C07K 14/575 - Hormones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/26 - Glucagons
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Apparatus for locating an attachment position for a reconstructed anterior cruciate ligament on an attachment surface of a bone comprises locating means 51, 61 arranged to locate at least one reference surface 4 of the bone and guide means 53, 54 arranged to define the attachment position in two dimensions on the attachment surface relative to the reference surface.

IPC Classes  ?

• A61B 17/17 - Guides for drills
• A61F 2/46 - Special tools for implanting artificial joints
• A61B 17/16 - Instruments for performing osteoclasisDrills or chisels for bonesTrepans
• A61F 2/08 - MusclesTendonsLigaments
• A61F 2/38 - Joints for elbows or knees
• A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis

Abstract

The invention relates to inhibitors of Von Willebrand Factor (VWF), and particularly to anti-VWF antibodies. The invention extends to compositions comprising the inhibitors, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the inhibitors, for example in therapy and diagnosis of conditions caused by platelet-mediated aggregation, including various cardiovascular diseases, such as acquired thrombotic thrombocytopenic purpura (aTTP), ischemic stroke and atherosclerosis.

IPC Classes  ?

• C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors

Abstract

The invention relates to inhibitors of Von Willebrand Factor (VWF), and particularly to anti-VWF antibodies. The invention extends to compositions comprising the inhibitors, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the inhibitors, for example in therapy and diagnosis of conditions caused by platelet-mediated aggregation, including various cardiovascular diseases, such as acquired thrombotic thrombocytopenic purpura (aTTP), ischemic stroke and atherosclerosis.

IPC Classes  ?

• C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors

Abstract

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the glucagon and GLP-1 receptors. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

IPC Classes  ?

• C07K 14/605 - Glucagons
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

This invention relates to retroviral gene transfer vectors, particularly lentiviral vectors, pseudotyped with hemagglutinin-neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, comprising a promoter and a transgene; and methods of making the same. The present invention also relates to the use of said vectors in gene therapy, particularly for the treatment of respiratory tract diseases such as Cystic Fibrosis (CF).

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

This invention relates to retroviral gene transfer vectors, particularly lentiviral vectors, pseudotyped with hemagglutinin-neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, comprising a promoter and a transgene; and methods of making the same. The present invention also relates to the use of said vectors in gene therapy, particularly for the treatment of respiratory tract diseases such as Cystic Fibrosis (CF).

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

This invention relates to retroviral gene transfer vectors, particularly lentiviral vectors, pseudotyped with hemagglutinin-neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, comprising a promoter and a transgene; and methods of making the same. The present invention also relates to the use of said vectors in gene therapy, particularly for the treatment of respiratory tract diseases such as Cystic Fibrosis (CF).

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

PYY-derived compounds comprising residues changed from the naturally-occurring peptide sequence and substituted, for example at their gamma-carboxylic acid groups, epsilon-amino groups or alpha-amino groups, with fatty dioic acid groups either directly or via short pendant oligopeptides. Related methods, compositions and uses, in particular for use in appetite suppression and the treatment or prevention of diabetes or obesity

IPC Classes  ?

• A61K 38/22 - Hormones
• A61K 38/26 - Glucagons
• A61P 3/04 - AnorexiantsAntiobesity agents
• C07K 14/575 - Hormones

Abstract

A sensor comprising an inlet and an outlet, a sensing chamber positioned between the inlet and the outlet, and a sensing element operatively connected to the sensing chamber, wherein the sensor comprises a first fibre formed from a drawable material, the fibre comprising a first channel extending between the inlet and the outlet, the sensing chamber being formed within the channel.

IPC Classes  ?

• G01N 21/85 - Investigating moving fluids or granular solids
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter

Abstract

The invention relates to a method for diagnosing a subject suffering from cancer, or a pre-disposition thereto. The method comprises detecting, in a bodily sample from a test subject, the concentration of a signature compound resulting from the metabolism of at least one sugar, and/or at least one amino acid or a precursor thereof, and/or at least one polyol present in a composition previously administered to the subject. The sugar is present in the composition at a concentration of more than 20,000 mg/100 ml, the amino acid or a precursor thereof is present in the composition at a concentration of at least 500 mg/ml, and the polyol is present in the composition at a concentration of more than 25,000 mg/100 ml. The method further comprises comparing this concentration with a reference for the concentration of the signature compound in an individual who does not suffer from cancer. In particular, an increase or decrease in the concentration of the signature compound compared to the reference, suggests that the subject is suffering from cancer, or has a pre-disposition thereto, or provides a negative prognosis of the subject's condition.

IPC Classes  ?

• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the glucagon and GLP-1 receptors. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

IPC Classes  ?

• A61P 3/04 - AnorexiantsAntiobesity agents
• C07K 14/605 - Glucagons

Abstract

A method of operating a flow cell. The method comprises providing a flow cell suitable for generating electrical power from hydrogen and a metal electrolyte. Said flow cell comprises a precipitate of metal oxi and said metal oxide comprises vanadium or manganese. The method further comprises electrochemically generating a redox active precipitate removal species from a precursor species, wherein said redox active precipitate removal species is capable of converting said metal oxide. The method further comprises exposing said metal oxide to said redox active precipitate removal species to effect conversion of the metal oxide.

IPC Classes  ?

• H01M 8/0656 - Combination of fuel cells with means for production of reactants or for treatment of residues with means for production of gaseous reactants by electrochemical means
• H01M 8/06 - Combination of fuel cells with means for production of reactants or for treatment of residues
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells

Abstract

There is provided herein a method of manufacturing a device comprising at least a first fibre using a draw apparatus, the method comprising: providing a first preform comprising a shape memory polymer to the draw apparatus; heating a first portion of the first preform; and drawing, using the draw apparatus, the heated first portion in order to form the first fibre.

IPC Classes  ?

• B29C 61/08 - Making preforms having internal stresses, e.g. plastic memory by stretching tubes
• B29C 53/60 - Winding and joining, e.g. winding spirally helically using internal forming surfaces, e.g. mandrels
• B29C 55/00 - Shaping by stretching, e.g. drawing through a dieApparatus therefor
• B29C 55/22 - Shaping by stretching, e.g. drawing through a dieApparatus therefor of tubes
• B29K 101/00 - Use of unspecified macromolecular compounds as moulding material
• B29K 105/00 - Condition, form or state of moulded material

Abstract

There is provided herein a preform for drawing fibres therefrom, the preform formed of east first material and having a non-uniform structure in the longitudinal direction and a method of forming the same.

IPC Classes  ?

• D01D 5/24 - Formation of filaments, threads, or the like with a hollow structureSpinnerette packs therefor
• B29B 11/14 - Making preforms characterised by structure or composition
• B29D 99/00 - Subject matter not provided for in other groups of this subclass
• C03B 37/012 - Manufacture of preforms for drawing fibres or filaments
• B33Y 80/00 - Products made by additive manufacturing
• B33Y 10/00 - Processes of additive manufacturing
• D01D 5/20 - Formation of filaments, threads, or the like with varying denier along their length
• D01D 5/30 - Conjugate filamentsSpinnerette packs therefor
• D01F 1/09 - Addition of substances to the spinning solution or to the melt for making electroconductive or anti-static filaments

Abstract

The invention relates to a method for diagnosing or for providing a prognosis of a subject suffering from oesophagogastric cancer, or a pre-disposition thereto. The method comprises analysing, in an endoluminal sample obtained from a test subject, the level of at least one biomarker compound selected from the group consisting of: acetone, acetic acid, butyric acid, pentanoic acid and hexanoic acid. The method further comprises comparing this level with a reference for the level of the at least one biomarker compound in an individual who does not suffer from oesophagogasatric cancer. In particular, an increase in the concentration of the at least one biomarker compound, in the endoluminal sample from the test subject, compared to the reference, suggests that the subject is suffering from oesophagogastric cancer, or has a pre-disposition thereto, or provides a negative prognosis of the subject's condition.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath

Abstract

The invention relates to ZIP12 antibodies. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis of hypoxia-related diseases, such as pulmonary hypertension and cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A redox flow battery comprising a gaseous anolyte and, as a catholyte, an organic redox active species having at least one electron directing moiety, wherein the organic redox active species is not unsubstituted parabenzoquinone.

IPC Classes  ?

• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells
• H01M 4/92 - Metals of platinum group
• H01M 8/103 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer having nitrogen, e.g. sulfonated polybenzimidazoles [S-PBI], polybenzimidazoles with phosphoric acid, sulfonated polyamides [S-PA] or sulfonated polyphosphazenes [S-PPh]

Abstract

The invention provides compounds of formula I, wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions.

IPC Classes  ?

• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 513/04 - Ortho-condensed systems

Abstract

The invention provides compounds of formula I, wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions.

IPC Classes  ?

• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 513/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone

Abstract

A resiliently deformable joint (2) having a proximal end (4), a distal end (6) and art axis (8), the resiliently deformable joint comprising a helical structure (12) comprising a plurality of integrally formed body portions (10), each of which body portions comprising a turn of the helical structure and being moveable relative to adjacent body portions, the resiliently deformable joint further comprising a plurality of body joint components (14), each of which body joint components is formed on a respective body portion such that adjacent body joint components are abuttable with one another to folly a body joint, the resiliently deformable joint further comprising first and second guides (22, 24) extending axially from the distal end to the proximal end of the resiliently deformable joint.

IPC Classes  ?

• A61B 1/008 - Articulations
• B33Y 10/00 - Processes of additive manufacturing
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

The present invention relates to a process for extracting oxidised metal pollutants from treated cellulosic or lignocellulosic biomass to recover the metal. The treatment also generates a cellulosic or lignocellulosic biomass which can to be used as a feedstock for biofuel, for making cellulose containing materials, and provides a source of other renewable chemicals.

IPC Classes  ?

• C08B 1/00 - Preparatory treatment of cellulose for making derivatives thereof
• C08H 8/00 - Macromolecular compounds derived from lignocellulosic materials
• B01D 11/02 - Solvent extraction of solids
• C07G 1/00 - Low-molecular-weight derivatives of lignin
• C07H 3/02 - Monosaccharides
• C12P 19/02 - Monosaccharides
• C13K 1/02 - GlucoseGlucose-containing syrups obtained by saccharification of cellulosic materials

Abstract

A surgical device (204) comprising a first tube (232) having an axis (233) and a wall with a channel extending axially within the wall, the first tube comprising a plurality of integrally-formed interlocking segments (234).

IPC Classes  ?

• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
• A61B 1/008 - Articulations
• A61B 17/00 - Surgical instruments, devices or methods
• A61M 25/00 - CathetersHollow probes

Abstract

The invention relates to the detection of biomarkers, and methods, compositions and kits for the detection of such biological markers for diagnosing various conditions, such as cancer. In particular, the invention relates to the detection of compounds as diagnostic and prognostic markers for detecting cancer, such as oesophago-gastric cancer.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath

Abstract

Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07D 487/04 - Ortho-condensed systems

Abstract

The disclosed non-volatile memory cell comprises a storage layer of an electrically insulating polarisable material in which data is recordable as a direction of electric polarisation, preferably of ferroelectric material, arranged between a magnetically frustrated layer, preferably of Mn-based antiperovskite piezomagnetic material and a conduction electrode. The magnetically frustrated layer has a different change in density of states relative to the conduction electrode in response to a change in electric polarisation of the storage layer, such that an electron or spin tunnelling resistance across the storage layer is dependent on the direction of electric polarisation.

IPC Classes  ?

• G11C 11/00 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor
• H01L 43/02 - Devices using galvano-magnetic or similar magnetic effects; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof - Details
• G11C 11/16 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements using elements in which the storage effect is based on magnetic spin effect
• H01L 27/22 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate using similar magnetic field effects
• H01L 43/10 - Selection of materials

Abstract

The disclosure provides a thermal desorption (TD) tube sampler. The sampler comprises a first connector configured to reversibly connect to a TD tube containing a sample, and a second connector configured to couple to a direct injection mass spectrometer. The TD tube sampler is configured to desorb a sample in a TD tube connected thereto, and feed the desorbed sample from the TD tube to a direct injection mass spectrometer such that the desorbed sample does not pass through a cold trap.

IPC Classes  ?

• H01J 49/40 - Time-of-flight spectrometers
• H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components
• G01N 30/72 - Mass spectrometers

Abstract

An implantable cardiovascular pressure sensor comprising a rigid enclosure sealed by a flexible membrane; and an elongate compliant member comprising a piezoelectric material, the member having a width and a length greater than the width, and two ends separated by the length and two sides separated by the width; wherein the flexible membrane is coupled to the elongate compliant member to transfer external fluid pressure load to the elongate compliant member to cause deflection of the elongate compliant member in response to changes in the external fluid pressure; the pressure sensor further comprising a first acoustic wave device provided by the piezoelectric material of the elongate compliant member for sensing said deflection.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0215 - Measuring pressure in heart or blood vessels by means inserted into the body

Abstract

An ear examination tool comprises a handle and a speculum mount coupled to the handle. The speculum mount is configured for retaining a disposable speculum. An spacing element is coupled to the handle and extends from the handle. A smartphone mount is coupled to the spacing element, and the spacing element is configured to maintain an optical separation distance between the speculum mount and the smartphone mount. The tool enables a clear view of the ear canal while allowing access by, and manipulation of, a microsuction tool being inserted into the ear canal. The extensive optical and data processing functionality of a “smartphone” can be integrated at low cost into an ear examination tool to provide a substantially improved piece of equipment for assisting in ear examination and microsuction of the ear.

IPC Classes  ?

• A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for ears, i.e. otoscopes
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
• A61B 1/32 - Devices for opening or enlarging the visual field, e.g. of a tube of the body
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 17/34 - TrocarsPuncturing needles

Abstract

An implantable intracardiac apparatus for implantation in a wall of the heart to secure a pressure sensor thereto, the apparatus comprising: a mesh configured to collapse to enable it to be carried, by a catheter, to a deployment site in the heart, and to expand upon deployment from the catheter to provide a conformable mesh layer for securement against the wall of the heart; wherein the conformable mesh layer comprises an opening occupied by a compliant diaphragm that is flush with the mesh layer, or recessed with respect to the mesh layer, when the mesh layer is secured against the wall of the heart; the apparatus further comprising a can for holding said pressure sensor, and the compliant diaphragm provides a wall of the can.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0215 - Measuring pressure in heart or blood vessels by means inserted into the body
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

A surgical instrument having a proximal end, a distal end and a shaft, the shaft comprising a plurality of joint components connected in series, each joint component comprising first and second connectors, which connectors are axially spaced apart from one another at first and second ends of a respective joint component, characterised in that the first connector comprises a first rolling surface, and the second connector comprise a second rolling surface, and wherein each joint component comprises a first spur gear extending from the first rolling surface, and a second spur gear extending from the second rolling surface, wherein the first rolling surface of a first joint component is engageable with the second rolling surface of a second joint component to form a rolling joint, and the second rolling surface of the first joint component is engageable with a first rolling surface of a third rolling joint.

IPC Classes  ?

• A61B 34/30 - Surgical robots
• A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
• B25J 9/10 - Programme-controlled manipulators characterised by positioning means for manipulator elements
• F16C 11/04 - Pivotal connections

Abstract

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the glucagon and GLP-1 receptors. With regard to in vivo properties, administration of example peptides of the invention has been shown, in animal models, to result in increased weight loss.

IPC Classes  ?

• C07K 14/605 - Glucagons
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/26 - Glucagons

Abstract

PYY-derived compounds comprising residues changed from the naturally-occurring peptide sequence and substituted, for example at their gamma-carboxylic acid groups, epsilon-amino groups or alpha-amino groups, with fatty dioic acid groups either directly or via short pendant oligopeptides. Related methods, compositions and uses, in particular for use in appetite suppression and the treatment or prevention of diabetes or obesity

IPC Classes  ?

• C07K 14/575 - Hormones

Abstract

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the glucagon and GLP-1 receptors. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly..

IPC Classes  ?

• A61K 38/26 - Glucagons
• A61P 3/04 - AnorexiantsAntiobesity agents
• C07K 14/575 - Hormones
• C07K 14/605 - Glucagons

Abstract

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the glucagon and GLP-1 receptors. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly..

IPC Classes  ?

• A61P 3/04 - AnorexiantsAntiobesity agents
• C07K 14/605 - Glucagons

Abstract

PYY-derived compounds comprising residues changed from the naturally-occurring peptide sequence and substituted, for example at their gamma-carboxylic acid groups, epsilon-amino groups or alpha-amino groups, with fatty dioic acid groups either directly or via short pendant oligopeptides. Related methods, compositions and uses, in particular for use in appetite suppression and the treatment or prevention of diabetes or obesity

IPC Classes  ?

• C07K 14/575 - Hormones

Abstract

The invention relates to a method for diagnosing a subject suffering from cancer, or a pre-disposition thereto. The method comprises detecting, in a bodily sample from a test subject, the concentration of a signature compound resulting from the metabolism of at least one sugar, and/or at least one amino acid or a precursor thereof, and/or at least one polyol present in a composition previously administered to the subject. The sugar is present in the composition at a concentration of more than 20,000mg/100ml, the amino acid or a precursor thereof is present in the composition at a concentration of at least 500 mg/ml, and the polyol is present in the composition at a concentration of more than 25,000mg/100ml. The method further comprises comparing this concentration with a reference for the concentration of the signature compound in an individual who does not suffer from cancer. In particular, an increase or decrease in the concentration of the signature compound compared to the reference, suggests that the subject is suffering from cancer, or has a pre-disposition thereto, or provides a negative prognosis of the subject's condition.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath

Abstract

The invention relates to biomarkers, and to novel biological markers for diagnosing various conditions, such as cancer. In particular, the invention relates to the use of these compounds as diagnostic and prognostic markers in assays for detecting cancer, such as pancreatic cancer and/or colorectal cancer, and corresponding methods of detection. The invention also relates to methods of determining the efficacy of treating these diseases with a therapeutic agent, and apparatus for carrying out the assays and methods. The assays are qualitative and/or quantitative, and are adaptable to large-scale screening and clinical trials.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention provides compositions and systems that allow the sensitive determination of the level of creatinine in a particular solution. Through the optimisation of enzymatic methods to detect creatinine the real-time determination of creatinine levels and creatinine clearance rates are also provided, allowing the real-time monitoring of kidney function. This is considered to be useful both in the monitoring of live subjects, and in the monitoring of isolated organs, such as a kidney, intended for transplantation.

IPC Classes  ?

• G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine
• C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Analogues of PYY differing from native human PYY by substitution of Ser23 with Ala23, Glu23, Lys23, Gln23 or AIB23. Further optional features include substitutions at further positions, loss of the Tyr1 residue of native human PYY and amidation of the C-terminus. Suitable for use as pharmaceuticals for treating and preventing disorders, in particular diabetes and obesity.

IPC Classes  ?

• C07K 14/575 - Hormones
• A61K 38/26 - Glucagons
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

There is provided herein a preform for drawing fibres therefrom, the preform formed of at least a first material and having a non-uniform structure in the longitudinal direction and a method of forming the same.

IPC Classes  ?

• D01D 5/00 - Formation of filaments, threads, or the like
• D01F 1/09 - Addition of substances to the spinning solution or to the melt for making electroconductive or anti-static filaments
• D01D 5/30 - Conjugate filamentsSpinnerette packs therefor
• D01D 5/24 - Formation of filaments, threads, or the like with a hollow structureSpinnerette packs therefor
• D01D 5/20 - Formation of filaments, threads, or the like with varying denier along their length
• B33Y 80/00 - Products made by additive manufacturing
• B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials

Abstract

There is provided herein a method of manufacturing a device comprising at least a first fibre using a draw apparatus, the method comprising: providing a first preform comprising a shape memory polymer to the draw apparatus; heating a first portion of the first preform; and drawing, using the draw apparatus, the heated first portion in order to form the first fibre.

IPC Classes  ?

• B29C 61/08 - Making preforms having internal stresses, e.g. plastic memory by stretching tubes
• B29C 53/14 - Twisting
• B29C 55/00 - Shaping by stretching, e.g. drawing through a dieApparatus therefor
• B29C 53/60 - Winding and joining, e.g. winding spirally helically using internal forming surfaces, e.g. mandrels
• B29C 55/22 - Shaping by stretching, e.g. drawing through a dieApparatus therefor of tubes

Abstract

A method of operating a flow cell. The method comprises providing a flow cell suitable for generating electrical power from hydrogen and a metal electrolyte. Said flow cell comprises a precipitate of metal oxi and said metal oxide comprises vanadium or manganese. The method further comprises electrochemically generating a redox active precipitate removal species from a precursor species, wherein said redox active precipitate removal species is capable of converting said metal oxide. The method further comprises exposing said metal oxide to said redox active precipitate removal species to effect conversion of the metal oxide.

IPC Classes  ?

• H01M 8/06 - Combination of fuel cells with means for production of reactants or for treatment of residues
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells
• H01M 8/0656 - Combination of fuel cells with means for production of reactants or for treatment of residues with means for production of gaseous reactants by electrochemical means

Abstract

A catalytic convertor comprising a substrate body (100) arranged within the catalytic convertor such that a principal flow of fluid through the catalytic convertor flows along a surface (101) of the substrate body, wherein said surface (101) has a plurality of openings (210) to micro-channels that extend away from said surface (101); and at least a portion of the surface (101) of the substrate body (100) comprises a catalytically active material, wherein the substrate body (100) is in the form of: a pellet; a sheet; solid elongate bodies; solid rods; a solid body having a plurality of bores; a non-tubular elongate body; a non-hollow body; a sheet curved in the form or a spiral; or a combination thereof.

IPC Classes  ?

• B01J 35/04 - Foraminous structures, sieves, grids, honeycombs
• C04B 38/04 - Porous mortars, concrete, artificial stone or ceramic warePreparation thereof by dissolving-out added substances
• F01N 3/28 - Construction of catalytic reactors
• B01J 21/04 - Alumina
• B01J 23/10 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of rare earths
• B01J 35/02 - Solids
• B01J 37/00 - Processes, in general, for preparing catalystsProcesses, in general, for activation of catalysts
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/08 - Heat treatment
• C04B 111/00 - Function, property or use of the mortars, concrete or artificial stone

Abstract

A redox flow battery comprising a gaseous anolyte and, as a catholyte, an organic redox active species having at least one electron directing moiety, wherein the organic redox active species is not unsubstituted parabenzoquinone.

IPC Classes  ?

• H01M 4/92 - Metals of platinum group
• H01M 8/1018 - Polymeric electrolyte materials
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells

Abstract

The present invention relates to a composite membrane for gas separation and/or nanofiltration of a feed stream solution comprising a solvent and dissolved solutes and showing preferential rejection of the solutes. The composite membrane comprises a separating layer with intrinsic microporosity. The separating layer is suitably formed by interfacial polymerisation on a support membrane. Suitably, at least one of the monomers used in the interfacial polymerisation reaction should possess concavity, resulting in a network polymer with interconnected nanopores and a membrane with enhanced permeability. The support membrane may be optionally impregnated with a conditioning agent and may be optionally stable in organic solvents, particularly in polar aprotic solvents. The top layer of the composite membrane is optionally capped with functional groups to change the surface chemistry. The composite membrane may be cured in the oven to enhance rejection. Finally, the composite membrane may be treated with an activating solvent prior to nanofiltration.

IPC Classes  ?

• B01D 71/72 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, not provided for in a single one of groups
• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 69/10 - Supported membranesMembrane supports
• B01D 69/12 - Composite membranesUltra-thin membranes
• B01D 53/22 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
• B01D 71/48 - Polyesters
• B01D 61/02 - Reverse osmosisHyperfiltration

Abstract

Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07D 487/04 - Ortho-condensed systems

Goods & Services

Reagents for medical and medical diagnostic use; sterile saline solutions for medical purposes; preparations, reagents and solutions to assist with the removal of polyps.

Abstract

The disclosed non-volatile memory cell comprises a storage layer of an electrically insulating polarisable material in which data is recordable as a direction of electric polarisation, preferably of ferroelectric material, arranged between a magnetically frustrated layer, preferably of Mn-based antiperovskite piezomagnetic material and a conduction electrode. The magnetically frustrated layer has a different change in density of states relative to the conduction electrode in response to a change in electric polarisation of the storage layer, such that an electron or spin tunnelling resistance across the storage layer is dependent on the direction of electric polarisation.

IPC Classes  ?

• H01L 43/08 - Magnetic-field-controlled resistors
• H01L 43/10 - Selection of materials
• H01L 45/00 - Solid state devices specially adapted for rectifying, amplifying, oscillating, or switching without a potential-jump barrier or surface barrier, e.g. dielectric triodes; Ovshinsky-effect devices; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof
• G11C 11/22 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using electric elements using ferroelectric elements
• G11C 11/16 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements using elements in which the storage effect is based on magnetic spin effect

Abstract

A surgical instrument comprising: a rigid shaft, at least one elbow joint hingedly coupled to the rigid shaft and a wrist joint coupled to the at least one elbow joint, wherein the wrist joint is configured to provide a first degree of freedom of movement and a second degree of freedom of movement, wherein the second degree of freedom of movement is substantially perpendicular to the first degree of freedom of movement.

IPC Classes  ?

• A61B 34/30 - Surgical robots
• A61B 18/14 - Probes or electrodes therefor
• A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61B 90/50 - Supports for surgical instruments, e.g. articulated arms

Abstract

The present invention related to identification of therapeutic agents of the treatment, diagnosis, and prevention of pulmonary hypertension.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 9/12 - Antihypertensives
• A61P 11/00 - Drugs for disorders of the respiratory system
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The disclosure provides a thermal desorption (TD) tube sampler. The sampler comprises a first connector configured to reversibly connect to a TD tube containing a sample, and a second connector configured to couple to a direct injection mass spectrometer. The TD tube sampler is configured to desorb a sample in a TD tube connected thereto, and feed the desorbed sample from the TD tube to a direct injection mass spectrometer such that the desorbed sample does not pass through a cold trap.

IPC Classes  ?

• G01N 1/28 - Preparing specimens for investigation
• G01N 30/00 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
• H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components

Abstract

The present application discloses a variety of airway sampling devices and associated methods. According to an embodiment, an airway sampling device for taking a sample from a subject's airway is provided with a handle to be gripped by a user when taking the sample and a sampling head carried by the handle, the sampling head comprising a cavity with an opening for entry by the sample and a sample collection membrane located within the cavity for receiving the sample.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

A non-volatile memory cell comprising: a storage layer comprised of a ferromagnetic or ferroelectric material in which data is recordable as a direction of magnetic or electric polarisation; a piezomagnetic layer comprised of an antiperovskite piezomagnetic material selectively having a first type of effect on the storage layer and a second type of effect on the storage layer dependent upon the magnetic state and strain in the piezomagnetic layer; and a strain inducing layer for inducing a strain in the piezomagnetic layer thereby to switch from the first type of effect to the second type of effect.

IPC Classes  ?

• G11C 11/00 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor
• H01L 43/10 - Selection of materials
• G11C 11/16 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements using elements in which the storage effect is based on magnetic spin effect
• G11C 11/22 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using electric elements using ferroelectric elements
• H01L 27/20 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including magnetostrictive components
• H01L 27/22 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate using similar magnetic field effects
• H01L 43/02 - Devices using galvano-magnetic or similar magnetic effects; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof - Details

Abstract

An implantable device for deployment inside a human or animal body, the device comprising at least one sensing component arranged to respond to an electrical signal having a known frequency band and at least one antenna comprising at least one antenna pole connected to the at least one sensing component, the antenna pole comprising at least one helical coil and a connecting stem.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• B60L 15/20 - Methods, circuits or devices for controlling the propulsion of electrically-propelled vehicles, e.g. their traction-motor speed, to achieve a desired performanceAdaptation of control equipment on electrically-propelled vehicles for remote actuation from a stationary place, from alternative parts of the vehicle or from alternative vehicles of the same vehicle train for control of the vehicle or its driving motor to achieve a desired performance, e.g. speed, torque, programmed variation of speed
• A61B 5/03 - Measuring fluid pressure within the body other than blood pressure, e.g. cerebral pressure
• A61B 5/07 - Endoradiosondes
• B60L 53/80 - Exchanging energy storage elements, e.g. removable batteries
• A61B 5/0215 - Measuring pressure in heart or blood vessels by means inserted into the body

Abstract

An implantable intravascular pressure sensor comprising a first transducer arranged to provide a pressure dependent signal in response to alternating electrical signals of a first frequency band, a second transducer arranged to provide a reference signal in response to alternating electrical signals of a second frequency band different from the first frequency band and an antenna coupling for sending and receiving said signals.

IPC Classes  ?

• A61B 5/0215 - Measuring pressure in heart or blood vessels by means inserted into the body
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/03 - Measuring fluid pressure within the body other than blood pressure, e.g. cerebral pressure
• G01L 19/08 - Means for indicating or recording, e.g. for remote indication
• G01L 19/14 - Housings

Abstract

An implantable intravascular device for deployment inside a human or animal, the apparatus comprising a body of crystalline material and a membrane of crystalline material fixed to the body by a hermetic bond an assembly of components carried on said crystalline material and arranged for responding to electrical signals wherein the body and the membrane at least partially encapsulate the assembly.

IPC Classes  ?

• A61B 5/0215 - Measuring pressure in heart or blood vessels by means inserted into the body
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• B23K 35/30 - Selection of soldering or welding materials proper with the principal constituent melting at less than 1550°C
• C22C 5/02 - Alloys based on gold
• G01L 13/00 - Devices or apparatus for measuring differences of two or more fluid pressure values
• H01Q 1/27 - Adaptation for use in or on movable bodies

Abstract

Hybrid photovoltaic-thermal collector A hybrid photovoltaic-thermal collector is described. The hybrid photovoltaic thermal collector (2) comprises a solar-thermal generator (8) for heating a working fluid using solar radiation in at least a Region II of the electromagnetic spectrum, and a photovoltaic cell (10) for generating electricity using solar radiation in a Region I of the electromagnetic spectrum, which is thermally decoupled from the solar-thermal generator. The collector does not include a solar concentrator.

IPC Classes  ?

• F24S 10/70 - Solar heat collectors using working fluids the working fluids being conveyed through tubular absorbing conduits
• H02S 40/44 - Means to utilise heat energy, e.g. hybrid systems producing warm water and electricity at the same time
• H01L 31/0525 - Cooling means directly associated or integrated with the PV cell, e.g. integrated Peltier elements for active cooling or heat sinks directly associated with the PV cells including means to utilise heat energy directly associated with the PV cell, e.g. integrated Seebeck elements
• F24S 10/20 - Solar heat collectors using working fluids having circuits for two or more working fluids
• F24S 10/25 - Solar heat collectors using working fluids having two or more passages for the same working fluid layered in the direction of solar rays, e.g. having upper circulation channels connected with lower circulation channels
• F24S 20/00 - Solar heat collectors specially adapted for particular uses or environments
• F24S 80/50 - Transparent coveringsElements for transmitting incoming solar rays and preventing outgoing heat radiation
• F24S 70/20 - Details of absorbing elements characterised by absorbing coatingsDetails of absorbing elements characterised by surface treatment for increasing absorption
• F24S 70/30 - Auxiliary coatings, e.g. anti-reflective coatings
• F24S 80/60 - Thermal insulation
• F24S 23/70 - Arrangements for concentrating solar rays for solar heat collectors with reflectors
• F24S 60/30 - Arrangements for storing heat collected by solar heat collectors storing heat in liquids

Abstract

mpp /Zpp p ; b) dividing each spectra into a plurality of m/z bins; c) determining a covariance or a partial covariance between different bins across the plurality of spectra and correlating the fluctuations of measured intensities in each bin; d) determining a statistical significance of each correlation to identify one or more true ion correlation peaks; e) obtaining a plurality of ion fragmentation patterns for one or more candidate parent ions; f) comparing the true ion correlation peaks to the candidate parent ion fragmentation patterns to determine if the candidate parent ion and the first parent ion are the same.

IPC Classes  ?

• H01J 49/00 - Particle spectrometers or separator tubes

Abstract

An implantable intravascular anchor for supporting a device inside a vascular lumen, the anchor comprising a first part configured to expand when extending from a catheter, and to collapse upon retraction into said catheter; a second part for supporting the device in the lumen and a third part, proximal to the first part, and configured so that, upon release from the catheter, it expands in width to engage an interior wall of the lumen and is adapted for securing the anchor against axial movement along the lumen.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0215 - Measuring pressure in heart or blood vessels by means inserted into the body
• A61B 5/026 - Measuring blood flow
• A61F 2/89 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure the wire-like elements comprising two or more adjacent rings flexibly connected by separate members
• B33Y 80/00 - Products made by additive manufacturing
• A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents

Abstract

An implantable device for sensing intravascular pressure, the device comprising a bulk acoustic wave (BAW) resonator arranged to be deflected by changes in intravascular fluid pressure to provide a pressure dependent sensing signal and an acoustic reflector arranged to separate the BAW resonator from the intravascular fluid and to mediate pressure from the intravascular fluid to the BAW resonator wherein the acoustic reflector comprises a layer structure arranged to provide a series of transitions in acoustic impedance between the intravascular fluid and the BAW resonator.

IPC Classes  ?

• A61B 5/0215 - Measuring pressure in heart or blood vessels by means inserted into the body
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to a process for extracting oxidised metal pollutants from treated cellulosic or lignocellulosic biomass to recover the metal. The treatment also generates a cellulosic or lignocellulosic biomass which can to be used as a feedstock for biofuel, for making cellulose containing materials, and provides a source of other renewable chemicals.

IPC Classes  ?

• C08B 1/00 - Preparatory treatment of cellulose for making derivatives thereof
• C08H 8/00 - Macromolecular compounds derived from lignocellulosic materials
• B01D 11/02 - Solvent extraction of solids
• C07G 1/00 - Low-molecular-weight derivatives of lignin
• C07H 3/02 - Monosaccharides
• C12P 19/02 - Monosaccharides
• C13K 1/02 - GlucoseGlucose-containing syrups obtained by saccharification of cellulosic materials

Abstract

A framework is provided for modeling the activity surrounding user credentials and/or machine level activity on a computer network using computer event logs by viewing the logs attributed to each user as a multivariate data stream. The methodology performs well in detecting compromised user credentials at a very low false positive rate. Such a methodology may detect both users of compromised credentials by external actors and otherwise authorized users who have begun engaging in malicious activity.

IPC Classes  ?

• H04L 29/06 - Communication control; Communication processing characterised by a protocol

Abstract

Herein is disclosed, a rechargeable flow battery, wherein the flow battery comprises: first and second electrodes, separated such that ions are allowed to flow between them, wherein a first reservoir comprising or for holding a first fluid electrolyte is fluidly connected to the first electrode, to allow circulation of the first fluid electrolyte from the first reservoir to the first electrode and from the first electrode to the first reservoir; and a first current collector comprising a layer of electrically conductive material having opposing first and second sides, wherein the first electrode is disposed on the first side of the first current collector, such that electrons can flow from the electrode to the first current collector, and a first layer of dielectric material is disposed on the second side of the first current collector.

IPC Classes  ?

• H01M 4/96 - Carbon-based electrodes
• H01M 8/0228 - Composites in the form of layered or coated products
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells

Abstract

The present invention relates to a process for preparing an asymmetric integrally skinned membrane for the separation of at least one solute from a solution, comprising the steps of: (a) preparing a polybenzimidazole dope solution comprising: (i) a polybenzimidazole polymer, and (ii) a solvent system for said polybenzimidazole which is water miscible; (b) casting a film of said dope solution onto a support; (c) immersing the film cast on the support into a coagulating medium to form an asymmetric integrally skinned membrane; (d) treating the membrane from step (c) with a cross-linking agent; (e) treating the membrane from step (d) with a cross-link modification agent. Further aspects relate to an asymmetric integrally skinned membrane and uses thereof.

IPC Classes  ?

• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 61/02 - Reverse osmosisHyperfiltration
• B01D 61/14 - UltrafiltrationMicrofiltration
• B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
• B01D 71/62 - Polycondensates having nitrogen-containing heterocyclic rings in the main chain

Abstract

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the glucagon and GLP-1 receptors. With regard to in vivo properties, administration of example peptides of the invention has been shown, in animal models, to result in increased weight loss.

IPC Classes  ?

• A61K 38/26 - Glucagons
• C07K 14/605 - Glucagons

Abstract

Analogues of PYY differing from native human PYY by substitution of Ser23 with Ala23, Glu23, Lys23, Gln23 or AIB23. Further optional features include substitutions at further positions, loss of the Tyr1 residue of native human PYY and amidation of the C-terminus. Suitable for use as pharmaceuticals for treating and preventing disorders, in particular diabetes and obesity.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/575 - Hormones

Abstract

The invention relates to the detection of biomarkers, and methods, compositions and kits for the detection of such biological markers for diagnosing various conditions, such as cancer. In particular, the invention relates to the detection of compounds as diagnostic and prognostic markers for detecting cancer, such as oesophago-gastric cancer.

IPC Classes  ?

• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 4-[[(7-aminopyrazolo[1,5- a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds (referred to herein as "APPAMP compounds") that, inter alia, inhibit (e.g., selectively inhibit) CDK (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK; and to treat disorders including: disorders that are associated with CDK; disorders that result from an inappropriate activity of a cyclin-dependent kinase (CDK); disorders that are associated with CDK mutation; disorders that are associated with CDK overexpression; disorders that are associated with upstream pathway activation of CDK; disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; cardiovascular disorders (including atherosclerosis); and autoimmune disorders (including rheumatoid arthritis). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Abstract

The invention relates to biomarkers, and to novel biological markers for diagnosing various conditions, such as cancer. In particular, the invention relates to the use of these compounds as diagnostic and prognostic markers in assays for detecting cancer, such as pancreatic cancer and/or colorectal cancer, and corresponding methods of detection. The invention also relates to methods of determining the efficacy of treating these diseases with a therapeutic agent, and apparatus for carrying out the assays and methods. The assays are qualitative and/or quantitative, and are adaptable to large- scale screening and clinical trials.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath

Abstract

An apparatus for guided wave testing of a test object comprises a linear array of receiver electromagnetic acoustic transducers (EMATs), and at least one linear array of transmitter EMATs disposed substantially parallel to the linear array of receiver EMATs and configured to launch guided waves in said test object in a direction substantially perpendicular to the at least one linear array of transmitter EMATs. Either (i) transmitter coils of the at least one linear array of transmitter EMATs have a common winding direction, receiver coils of adjacent receiver EMATs have alternating winding directions, and receiver coils of at least two adjacent receiver EMATs are connected in series, or (ii) transmitter coils of the transmitter EMATs have alternating winding directions, receiver coils of adjacent receiver EMATs have a common winding direction, and receiver coils of at least two adjacent receiver EMATs are connected in series.

IPC Classes  ?

• G01N 29/04 - Analysing solids
• G01N 29/22 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object Details
• G01N 29/24 - Probes
• G01N 29/32 - Arrangements for suppressing undesired influences, e.g. temperature or pressure variations

Abstract

The invention provides compositions and systems that allow the sensitive determination of the level of creatinine in a particular solution. Through the optimisation of enzymatic methods to detect creatinine the real-time determination of creatinine levels and creatinine clearance rates are also provided, allowing the real-time monitoring of kidney function. This is considered to be useful both in the monitoring of live subjects, and in the monitoring of isolated organs, such as a kidney, intended for transplantation.

IPC Classes  ?

• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine

Abstract

The present invention provides a multi-block copolymer comprising at least blocks A-B-A or B-A-B, wherein block A comprises a polyester formed by polymerisation of a lactone and/or a lactide; and block B comprises a copolyester formed by polymerisation of an epoxide and an anhydride, or a polycarbonate formed by polymerisation of an epoxide and carbon dioxide, and methods of production thereof.

IPC Classes  ?

• C08G 63/08 - Lactones or lactides
• C08G 63/82 - Preparation processes characterised by the catalyst used
• B01J 31/22 - Organic complexes
• C08G 63/42 - Cyclic ethersCyclic carbonatesCyclic sulfitesCyclic orthoesters
• C08G 63/64 - Polyesters containing both carboxylic ester groups and carbonate groups
• C08G 81/02 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
• C08G 101/00 - Manufacture of cellular products

Abstract

There is provided a regenerative fuel cell capable of operating in a power delivery mode in and in an energy storage mode. The cell may comprise a reversible hydrogen gas anode, in an anode compartment, a reversible cathode in a cathode compartment, and a membrane separating the anode compartment from the cathode compartment, which membrane is capable of selectively passing protons. an additive may be provided in the cathode compartment.

IPC Classes  ?

• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells
• H01M 8/1009 - Fuel cells with solid electrolytes with one of the reactants being liquid, solid or liquid-charged
• H01M 8/04186 - Arrangements for control of reactant parameters, e.g. pressure or concentration of liquid-charged or electrolyte-charged reactants
• H01M 4/96 - Carbon-based electrodes

Abstract

A method for controlling conditions within a liquid conduit system. The method comprising: defining a zone within the liquid conduit system, wherein pressure within the zone is influenced by one or more actuator valves; controlling the one or more actuator valves in dependence on a Pareto efficient solution to the minimisation of functions of the average pressure within the zone (AZP) and the pressure variability within the zone (PVZ).

IPC Classes  ?

• E03B 7/07 - Arrangement of devices, e.g. filters, flow controls, measuring devices, siphons or valves, in the pipe systems
• G05D 16/20 - Control of fluid pressure characterised by the use of electric means
• E03B 7/02 - Public or like main pipe systems

Abstract

The present disclosure relates to an improved method for treating a lignocellulose biomass in order to dissolve the lignin therein, while the cellulose does not dissolve. The cellulose pulp obtained can be used to produce glucose. In addition the lignin can be isolated for subsequent use in the renewable chemical industry.

IPC Classes  ?

• D21C 3/00 - Pulping cellulose-containing materials
• C12P 19/02 - Monosaccharides
• D21C 9/02 - Washing
• C13K 1/02 - GlucoseGlucose-containing syrups obtained by saccharification of cellulosic materials
• C12P 19/14 - Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase, e.g. by alpha-amylase
• D21C 3/04 - Pulping cellulose-containing materials with acids, acid salts, or acid anhydrides
• D21C 3/20 - Pulping cellulose-containing materials with organic solvents
• D21C 1/04 - Pretreatment of the finely-divided materials before digesting with acid reacting compounds
• D21H 11/12 - Pulp from non-woody plants or crops, e.g. cotton, flax, straw or bagasse
• D21C 5/00 - Other processes for obtaining cellulose, e.g. cooking cotton linters
• C13K 13/00 - Sugars not otherwise provided for in this class
• D21C 11/00 - Regeneration of pulp liquors